Complete results of the first randomized, placebo-controlled study of bosentan, a dual endothelin receptor antagonist, in pulmonary arterial hypertension

Current Therapeutic Research - Clinical and Experimental

Volumn 63, Issue 4, 2002, Pages 227-246

  Badesch, David B ^a   Bodin, Frédéric ^b   Channick, Richard N ^c   Frost, Adaani ^d   Rainisio, Maurizio ^e   Robbins, Ivan M ^f   Roux, Sébastien ^b   Rubin, Lewis J ^c   Simonneau, Gérald ^g   Sitbon, Olivier ^g   Tapson, Victor F ^h  

^a UNIVERSITY OF COLORADO   (United States)

^b ACTELION PHARMACEUTICALS LTD   (Switzerland)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

^e Statistics for Research Ltd   (Switzerland)

^f VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g HÔPITAL ANTOINE BÉCLÈRE   (France)

^h DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Bosentan; Endothelin receptors; Endothelins; Pulmonary hypertension; Systemic scleroderma

Indexed keywords

ANTICOAGULANT AGENT; BOSENTAN; ENDOTHELIN A RECEPTOR ANTAGONIST; ENDOTHELIN B RECEPTOR ANTAGONIST; ENDOTHELIN RECEPTOR ANTAGONIST; PLACEBO; VASODILATOR AGENT;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; DYSPNEA; EXERCISE; FEMALE; HEADACHE; HEMODYNAMIC PARAMETERS; HUMAN; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; PROGNOSIS; PULMONARY HYPERTENSION; RANDOMIZED CONTROLLED TRIAL; SCLERODERMA; TREATMENT OUTCOME;

EID: 0036263877     PISSN: 0011393X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0011-393X(02)80029-7     Document Type: Article

References (44)

1. Primary pulmonary hypertension
2. Diagnosis and treatment of pulmonary hypertension associated with collagen diseases
3. Long-term prostacyclin for pulmonary hypertension with associated congenital heart defects
4. Appetite-suppressant drugs and the risk of primary pulmonary hypertension
5. Primary pulmonary hypertension associated with human immunodeficiency virus infection
6. Primary pulmonary hypertension: Natural history and the importance of thrombosis
7. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension
8. Pharmacc dynamic profile of prostacyclin
9. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension
10. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial
11. Long-term treatment of primary pulmonary hypertension with aerosolized iloprost, a prostacyclin analogue
12. Orally active prostacyclin analogue in primary pulmonary hypertension
13. UT-15. Treatment of pulmonary hypertension, treatment of peripheral vascular disease
14. Endothelin-1: A mediator of pulmonary hypertension?
15. Endothelin mediates pulmonary vascular remodelling in a canine model of chronic embolic pulmonary hypertension
16. Relation of endothelin-1 to survival in patients with primary pulmonary hypertension
17. Endothelin and collagen vascular disease: A review with special reference to Raynaud's phenomenon and systemic sclerosis
18. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension
19. Endothelin-receptor antagonist bosentan prevents and reverses hypoxic pulmonary hypertension in rats
20. Nonspecific endothelin-receptor antagonist blunts monocrotaline-induced pulmonary hypertension in rats
21. Bosentan prevents hypoxia-reoxygenation-induced pulmonary hypertension and improves pulmonary function
22. Hemodynamic effects of bosentan, an endothelin receptor antagonist, in patients with pulmonary hypertension
23. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: A randomised placebo-controlled study
24. The 6-minute walk: A new measure of exercise capacity in patients with chronic heart failure
25. Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension. Comparison with cardiopulmonary exercise testing
26. Psychophysical bases of perceived exertion
27. Endothelin antagonism with bosentan: A review of potential applications
28. Protection from pulmonary hypertension with an orally active endothelin receptor antagonist in hypoxic rats
29. Endothelin-1 stimulates DNA synthesis and proliferation of pulmonary artery smooth muscle
30. Update of REACH-1 and MER1T-HF clinical trials in heart failure
31. Long-term, open-label experience with an endothelin receptor antagonist, bosentan, in patients with severe chronic heart failure
32. Cellular signaling by peptides of the endothelin gene family
33. Endothelin receptor subtype B mediates synthesis of nitric oxide by cultured bovine endothelial cells
34. Acute pro-inflammatory actions of endothelin-1 in the guinea-pig lung: Involvement of ETA and ETB receptors
35. Endothelin B receptor-mediated contraction in human pulmonary resistance arteries
36. Endothelins
37. Endothelin antagonists
38. Vasodilator effects of endothelin-converting enzyme inhibition and endothelin ETA receptor blockade in chronic heart failure patients treated with ACE inhibitors
39. Expression of endothelin-1, ETA and ETB receptors, and ECE and distribution of endothelin-1 in failing rat heart
40. Altered endothelin receptor subtype expression in hepatic injury after ischemia/reperfusion
41. Elevated perfusion pressure upregulates endothelin-1 and endothelin B receptor expression in the rabbit carotid artery
42. Increased levels of endothelin-1 and differential endothelin type A and B receptor expression in scleroderma-associated fibrotic lung disease
43. Role of endothelin in the increased vascular tone of patients with essential hypertension